Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood

Cytotherapy. 2010 Oct;12(6):713-20. doi: 10.3109/14653249.2010.517518.


Because of the necessary immunodepletion prior to cord blood transplantation as well as the immaturity of cord blood immune cells, recipients experience a high incidence of viral infection in addition to complications observed after hematopoietic stem cell transplantation, such as relapse and graft-versus-host disease. We describe current immunotherapeutic approaches to treating these complications, including the generation of antigen-specific T cells from cord blood, redirecting cord blood T cells using chimeric antigen receptors, and generating cord blood-derived natural killer cells and regulatory T cells.

Publication types

  • Review

MeSH terms

  • Cord Blood Stem Cell Transplantation* / adverse effects
  • Fetal Blood / cytology
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / therapy*
  • Humans
  • Immunotherapy, Adoptive*
  • Killer Cells, Natural / immunology
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / metabolism
  • Recombinant Fusion Proteins / genetics
  • T-Lymphocyte Subsets / cytology
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocytes, Regulatory / cytology
  • T-Lymphocytes, Regulatory / immunology
  • T-Lymphocytes, Regulatory / metabolism
  • Transplantation Conditioning* / adverse effects
  • Virus Diseases / etiology
  • Virus Diseases / immunology
  • Virus Diseases / therapy*


  • Receptors, Antigen, T-Cell
  • Recombinant Fusion Proteins